Neurocrine Biosciences (NBIX) Debt Ratio (2018 - 2024)

Neurocrine Biosciences (NBIX) posted quarterly Debt Ratio of 0.04 for Q1 2024, down 32.4% on a QoQ basis from 0.05 in Q4 2023.

Neurocrine Biosciences (NBIX) Debt Ratio (2018 - 2024) Analysis & Trends

Neurocrine Biosciences has reported Debt Ratio for 6 years, with the latest figure at 0.04 in Q1 2024.

Debt Ratio for Q1 2024 came in at 0.04, changed N/A year-over-year; the trailing twelve-month figure through Mar 2024 was 0.04 (changed N/A YoY), and the FY2023 annual result was 0.05, down 26.85% from the prior year.
Debt Ratio fell to 0.04 in Q1 2024, from 0.05 in the prior quarter.
Over five years, Debt Ratio peaked at 0.28 in Q3 2020 and troughed at 0.04 in Q1 2024.
A 4-year average of 0.12 and a median of 0.07 in 2022 frame the typical range for Debt Ratio.
The largest YoY upside for Debt Ratio was 24.43% in 2023 against a maximum downside of 26.85% in 2023.
A 4-year view of Debt Ratio shows it stood at 0.28 in 2020, then tumbled by 74.72% to 0.07 in 2022, then decreased by 26.85% to 0.05 in 2023, then tumbled by 32.4% to 0.04 in 2024.
Per Business Quant data, the three most recent Debt Ratio figures were 0.04 in Q1 2024, 0.05 in Q4 2023, and 0.06 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Haleon	43.65 Bn	42.68 Bn	-	-0.13
2	Teva Pharmaceutical Industries	43.09 Bn	39.44 Bn	2.15 Bn	0.42
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	0.60
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	0.32
5	United Therapeutics	22.11 Bn	19.45 Bn	683.80 Mn	-
6	Viatris	18.77 Bn	17.88 Bn	1.46 Bn	0.38
7	Neurocrine Biosciences	15.62 Bn	15.23 Bn	935.80 Mn	-
8	Elanco Animal Health	12.07 Bn	11.54 Bn	798.00 Mn	0.29
9	Dr Reddys Laboratories	10.09 Bn	9.93 Bn	-	0.12
10	Alkermes	8.20 Bn	7.54 Bn	397.90 Mn	0.34

Download Data